Status:
COMPLETED
68Ga-DOTATATE PET for Management of Neuroendocrine Tumors
Lead Sponsor:
University Health Network, Toronto
Conditions:
Neuroendocrine Tumors
Eligibility:
All Genders
14+ years
Phase:
NA
Brief Summary
This is a research study to collect information regarding usefulness of positron emission tomography (PET) scans using a special dye called 68Ga-DOTATATE for patients with neuroendocrine tumours by de...
Detailed Description
When patients are suspected of having neuroendocrine tumours, they will usually undergo various imaging scans such as computed tomography (CT) scan and magnetic resonance imaging (MRI), and octreotide...
Eligibility Criteria
Inclusion
- Able to undergo PET/CT without sedation
- Any of the following indications:
- Group A. Identification of primary tumor: For the initial diagnosis of patients with clinical (e.g., signs, symptoms) and/or biochemical (e.g., tumor markers) suspicion of neuroendocrine tumours (NETs) but for whom conventional imaging is negative or equivocal or for whom biopsy is not easily obtained.
- Group B. Staging: For the staging of patients with localized primary NETs and/or limited metastasis where definitive surgery is planned.
- Group C. Restaging: Restaging of patients with NET where surgery or peptide-receptor radiotherapy (PRRT) is being considered; OR, where conventional imaging is negative or equivocal at time of clinical and/or biochemical progression.
- Group D. As a problem-solving tool: As a problem-solving tool in patient with NET when confirmation of site of disease and/or disease extent may impact clinical management.
- Approved by a review panel if Group D.
Exclusion
- Inability to provide informed consent.
- Contraindication for PET examination as per institutional safety guidelines, including but not limited to pregnancy, or inability to lie still for PET examination.
- Need for full sedation to undergo PET/CT scan.
Key Trial Info
Start Date :
March 28 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 30 2023
Estimated Enrollment :
1916 Patients enrolled
Trial Details
Trial ID
NCT03873870
Start Date
March 28 2019
End Date
April 30 2023
Last Update
January 17 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Princess Margaret Cancer Centre
Toronto, Ontario, Canada, M5G 2M9